Statin-fibrate combination: therapy for hyperlipidemia: a review
about
A comprehensive review on metabolic syndromeStrategies to rescue steatotic livers before transplantation in clinical and experimental studiesAnti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a reviewDyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentPathophysiology of dyslipidaemia in the metabolic syndrome.Plasma cholesterol and related lipid levels of seemingly healthy public service employees in Kampala, Uganda.JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.Lipid-lowering therapies in development.Prevention and treatment of the metabolic syndrome.Matrix metalloproteinases and diabetic vascular complications.Fluvastatin: efficacy and safety in reducing cardiac events.Secondary prevention of ischemic cerebrovascular disease. What is the evidence?FIELD study.Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles.Fibrates after the FIELD study: Some answers, more questions.Dyslipidaemia in diabetic patients: time for a rethink.Endothelial function, arterial stiffness and lipid lowering drugs.Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.Fibrates: where are we now?Highly stereoselective hydrogenations--as key-steps in the total synthesis of statins.Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future.A Systems Biology Approach for Identifying Hepatotoxicant Groups Based on Similarity in Mechanisms of Action and Chemical Structure.Molecular determinants of differential pore blocking of kidney CLC-K chloride channels.ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden.Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.A practical approach to lipid management in the elderly.Raised plasma fibrinogen concentration in patients with abdominal aortic aneurysm.
P2860
Q21284500-0E630D46-E967-4019-B129-CE826B818909Q27003912-4863893B-644E-4E97-93AA-69A1516F463FQ34238630-D8F229EE-1CB4-455E-8487-1E2C91E95412Q35029623-FC7ADE41-D1A6-4D3D-A472-AA88017A4B1FQ35522107-63D3F42C-0BF5-4A52-B772-C817BC86FB73Q35697590-39690C7F-8DF9-4492-81A3-596C5DCD53D6Q35808362-CAF184A0-FC5B-4ADD-BDA4-4F11B6D989E6Q35925570-A375EEEB-82E3-42A3-BC17-D1E200D5FF27Q35952447-4D339A9D-ECCE-4DBC-8971-E12E64124813Q36081593-77694A89-D743-4006-ACAA-04F19DA304B6Q36249930-4BC19DED-9FBC-4A60-8050-9EEA642CE312Q36271814-32B2DA7F-EED6-4204-BA26-3DC374F289B7Q36522005-8188D0FA-274E-4653-B014-94C40FF870C4Q36675450-5C6E3F90-128C-40E5-A7C3-AADC4AB5517CQ36679599-620D7D37-D09A-479C-A203-ABF8B4F1A7D6Q36909519-A35366DB-D2C2-42F8-BC95-43942D314DFDQ36936335-C7E9D187-62B2-4F90-B8CF-B38C0968961FQ37019924-68785524-59DF-4766-8957-32DE1F22571EQ37368691-6395BE6F-3F4A-445D-A034-87D0A7974A9BQ37629758-B4E86D32-8EC0-4053-A5ED-982BE675348AQ37677573-5618187B-87EE-40AD-B494-DD4128A30897Q38001736-DF3F2D15-C2DD-4A89-ACD8-97C8402BC7E7Q38014975-47EA1D3B-3777-4653-AD1A-05D7463E8D0FQ38042090-08793E1C-E5D7-4B82-B0E3-7D4947E90DD0Q38684663-271183D4-C45C-44A3-9163-C259D6C2BFE3Q39677914-0CF1A522-92A8-4B28-B425-1520B8B675E4Q40102720-12F053CB-4284-4021-9B1A-6E577A943E86Q44742669-708FFE3E-584F-4E71-842C-C8829857F81EQ46395433-90DFFA2C-B761-47C0-99C0-4586C6A63875Q48703659-7A59622B-8E51-45BB-A755-946EA478D1FEQ52854977-7413B68B-53C3-4C1C-81AF-4739FD9F9685
P2860
Statin-fibrate combination: therapy for hyperlipidemia: a review
description
2003 nî lūn-bûn
@nan
2003 թուականին հրատարակուած գիտական յօդուած
@hyw
2003 թվականին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Statin-fibrate combination: therapy for hyperlipidemia: a review
@ast
Statin-fibrate combination: therapy for hyperlipidemia: a review
@en
Statin-fibrate combination: therapy for hyperlipidemia: a review
@nl
type
label
Statin-fibrate combination: therapy for hyperlipidemia: a review
@ast
Statin-fibrate combination: therapy for hyperlipidemia: a review
@en
Statin-fibrate combination: therapy for hyperlipidemia: a review
@nl
prefLabel
Statin-fibrate combination: therapy for hyperlipidemia: a review
@ast
Statin-fibrate combination: therapy for hyperlipidemia: a review
@en
Statin-fibrate combination: therapy for hyperlipidemia: a review
@nl
P2093
P1476
Statin-fibrate combination: therapy for hyperlipidemia: a review
@en
P2093
A S Wierzbicki
D P Mikhailidis
M Schacter
W G Simpson
P304
P356
10.1185/030079903125001668
P407
P577
2003-01-01T00:00:00Z